The psychedelic sector never sits still. Here is what happened during the week of September 29 – October 5, 2025, and why each story matters for the companies and investors we track.
Reunion Neuroscience Inc. (Private): Reunion doses first patient in REKINDLE Phase 2 trial of RE104
Reunion Neuroscience dosed the first patient in REKINDLE, a Phase 2 trial evaluating its serotonergic candidate RE104 for adjustment disorder in patients with cancer and other serious medical illnesses. Topline results are anticipated in 2027. The start follows the company's upsized $133 million Series A closing earlier in September.
Source: reunionneuro.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.